Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for High-Risk Ph-negative ALL in Young Adults
NCT04334993Phase 2Unknown
- Sponsor
- Israel Medical Association
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), mixed phenotype acute leukemia (MPAL), sponsored by Israel Medical Association. Status: unknown.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04334993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334993.